18 februari 2015: bron: European Prospective Investigation Into Cancer and Nutrition (EPIC)

Wanneer vrouwen veel foliumzuur nemen via voeding dan verminderen zij significant het risico op hormoonreceptor negatieve borstkanker te krijgen voor zij in de overgang komen. Dit blijkt uit een langjarige - 11,5 jaar - studie in tien verschillende Europese landen onder totaal 367,993 vrouwen.

Foliumzuur komt voor in bepaalde groenten en fruit maar ook veel in gekookte kippenlever en gekookte runderlever. Zie hier een tabel van de website over foliumzuurbijkinderwens:

foliumzuur in voeding tabel

Studieresultaten:

Vrouwen in het hoogste quintile van foliumzuurinname  hadden net een significant verminderd risico op borstkanker overall versus vrouwen in het laagste quintile (hazard ratio = 0.92, 95% confidence interval = 0.83–1.01, P = .037 for trend).

Premenopausale vrouwen (vrouwen voor de overgang) in het hoogste versus laagste quintile hadden een significant verminderd risico op het ontwikkelen van hormoon-receptorn-negatieve borstkanker (AR neg.)  (HR = 0.66, 95% CI = 0.45–0.96, P = .042 for trend) en progesteron receptor–negatieve borstkanker (PR-neg) (HR = 0.70, 95% CI = 0.51–0.97, P = .021 for trend).

er werd geen significant verschil gevonden op het risico op borstkanker bij vrouwen na de overgang.

Onder vruwen die veel alcohol gebruikten  (meer dan 12 alcoholische drankjes per week), hadden die vrouwen in het hoogste quintile van inname van folliumzuur versus laagste quintile een significant verminderd risico op borstkanker overall.   (HR = 0.86, 95% CI = 0.75–0.98, P = .035 for interaction).

Conclusie:

De onderzoekers concluderen dan ook : “Hoge inname van foliumzuur via voeding is gerelateerd aan een verminderd risico op receptor-negatieve borstkanker bij premenopauzale vrouuwen .”

Het volledige studierapport: Dietary Folate Intake and Breast Cancer Risk: European Prospective Investigation Into Cancer and Nutrition is tegen betaling in te zien.

Hier het abstract van deze studie:

“Higher dietary folate intake may be associated with a lower risk of sex hormone receptor–negative breast cancer in premenopausal women.”

Source: 

  1. JNCI J Natl Cancer Inst 107 (1): dju367 doi: 10.1093/jnci/dju367

Dietary Folate Intake and Breast Cancer Risk: European Prospective Investigation Into Cancer and Nutrition

  1. I. Romieu

+ Author Affiliations

  1. Affiliations of authors: International Agency for Research on Cancer (IARC), Lyon, France (JdB, PF, VC, JYP, NS, FM, IR); Section for Epidemiology, Department of Public Health, Aarhus University, Aarhus, Denmark (KO); Danish Cancer Society Research Center, Copenhagen, Denmark (NR, AT); Inserm, Centre for research in Epidemiology and Population Health (CESP), Villejuif, France (MCBR, FCC, GF); Université Paris Sud, Villejuif, France (MCBR, FCC, GF); Institute Gustave Roussy, Villejuif, France (MCBR, FCC, GF); Department of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany (VK, RK); Department of Epidemiology, German Institute of Human Nutrition, Potsdam-Rehbrücke, Germany (MMB); Hellenic Health Foundation, Athens, Greece (AT, DT); Department of Hygiene, Epidemiology and Medical Statistics, University of Athens Medical School, Athens, Greece (PL); Department of Epidemiology, Harvard School of Public Health, Boston, MA (PL, DT); Bureau of Epidemiologic Research, Academy of Athens, Athens, Greece (PL, DT); Molecular and Nutritional Epidemiology Unit, Cancer Research and Prevention Institute – ISPO, Florence, Italy (DP); Epidemiology and Prevention Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy (SSi); Dipartimento di medicina clinica e chirurgia, Federico II University, Naples, Italy (SP); Cancer Registry and Histopathology Unit, “Civic - M.P.Arezzo” Hospital, Ragusa, Italy (RT); Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK (PV, HBBdM, PHP, ER); HuGeF Foundation, Torino, Italy (PV); National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands (HBBdM); Department of Gastroenterology and Hepatology, University Medical Centre, Utrecht, the Netherlands (HBBdM); Department of Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the Netherlands (PHP); Department of Nutrition, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway (AH); Department of Community Medicine, Faculty of Health Sciences, UiT The Arctic University of Norway, Tromsø, Norway (DE, EW); Department of Research, Cancer Registry of Norway, Oslo, Norway (EW); Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden (EW); Samfundet Folkhälsan, Helsinki, Finland (EW); Public Health Directorate, Asturias, Spain (SSá); Unit of Nutrition, Environment and Cancer, Cancer Epidemiology Research Programme, Catalan Institute of Oncology (ICO), Barcelona, Spain (NT); Escuela Andaluza de Salud Pública, Granada, Spain (MJS); CIBER de Epidemiología y Salud Pública (CIBERESP), Spain (MJS, MDC, ABG); Instituto de Investigación Biosanitaria de Granada (Granada.bs), Granada, Spain (MJS); Public Health Division of Gipuzkoa, Donostia-San Sebastian, Spain (PA); Department of Epidemiology, Murcia Regional Health Authority, Murcia, Spain (MDC); Navarre Public Health Institute, Pamplona, Spain (ABG); University of Cambridge and Nick Wareham, MRC Epidemiology Unit, University of Cambridge, Cambridge, UK (KTK); Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK (TJK, KEB); Department of Clinical Sciences, Lund University, Malmö, Sweden (UE, ES); Department of Pharmacology and Clinical Neuroscience, Clinical Pharmacology unit, Umeå University, Umeå, Sweden (BVG, JS).
  1. Correspondence to: Jordi de Batlle, PhD, International Agency for Research on Cancer, 150 cours Albert Thomas, Lyon 69008, France (e-mail: jordidebatlle@gmail.com).
  • Received January 16, 2014.
  • Revision received May 30, 2014.
  • Accepted October 6, 2014.

Abstract

Background: There is limited evidence on the association between dietary folate intake and the risk of breast cancer (BC) by hormone receptor expression in the tumors. We investigated the relationship between dietary folate and BC risk using data from the European Prospective Investigation into Cancer and Nutrition (EPIC).

Methods: A total of 367993 women age 35 to 70 years were recruited in 10 European countries. During a median follow-up of 11.5 years, 11575 women with BC were identified. Dietary folate intake was estimated from country-specific dietary questionnaires. Cox proportional hazards regression models were used to quantify the association between dietary variables and BC risk. BC tumors were classified by receptor status. Subgroup analyses were performed by menopausal status and alcohol intake. Intake of other B vitamins was considered. All statistical tests were two-sided.

Results: A borderline inverse association was observed between dietary folate and BC risk (hazard ratio comparing top vs bottom quintile [HRQ5-Q1] = 0.92, 95% CI = 0.83 to 1.01, P trend = .037). In premenopausal women, we observed a statistically significant trend towards lower risk in estrogen receptor-negative BC (HRQ5-Q1 = 0.66, 95% CI = 0.45 to 0.96, P trend = .042) and progesterone receptor-negative BC (HRQ5-Q1 = 0.70, 95% CI = 0.51 to 0.97, P trend = .021). No associations were found in postmenopausal women. A 14% reduction in BC risk was observed when comparing the highest with the lowest dietary folate tertiles in women having a high (>12 alcoholic drinks/week) alcohol intake (HRT3-T1 = 0.86, 95% CI = 0.75 to 0.98, P interaction = .035).

Conclusions: Higher dietary folate intake may be associated with a lower risk of sex hormone receptor–negative BC in premenopausal women.


Plaats een reactie ...

Reageer op "Foliumzuur via voeding geeft significant minder risico op hormoon-receptor-negatieve borstkanker bij vrouwen in leeftijd voor de overgang"


Gerelateerde artikelen